Location permission needed for a better experience.
How can we help you?
EN
Hızlı Randevu
Hastane
Randevusu
Görüntülü Görüşme Randevusu

18 yaş ve üstü hastalar kabul edilmektedir. Profesör veya doçent doktor tercihinizde öğretim üyesi farkı oluşabilir. Ayrıca kurumlara ait uygulama esasları farklılık gösterebilir.

Education
  • 1995 - 2012 Akdeniz University Faculty of Medicine
  • 2006 Professor
  • 2000 - 2006 Associate Professor
  • 2002 University of Wales College of Medicine, Dept of Hematoloji Cardiff/ İngiltere (moleküler tekniklerin hematolojide kullanımı)
  • 1995 - 2000 Yardımcı Associate Professor
  • 1995 İstanbul University İstanbul Faculty of Medicine Hematoloji
  • 1992 Şişli Etfal Eğitim ve Araştırma Hospital İç Hastalıkları
  • 1985 Ankara University Faculty of Medicine
Experience
  • 2022 Acıbadem Healthcare Services
  • 2016 - 2021 Hisar Intercontinental hastanesi hematoloji ve kök hücre nakil ünitesi sorumlu hekimliği
  • 2012 - 2016 EMSEY hastanesi hematoloji ve kök hücre nakil ünitesi kurulması ve sorumlu hekimliği
  • 1995 - 2012 Akdeniz University Faculty of Medicine Faculty Member
  • 1985 - 1987 Zorunlu Hizmet
Memberships
  • European Haematology Association
  • Hemaferez Association
  • Kan Merkezleri ve Transfüzyon Association
  • Türk Hematoloji Association
  • İstanbul Tabip Odası
PUBLICATIONS
  • Ionizing Radiation Exposure due to Medical Imaging in Hematopoietic Stem Cell Transplant Recipients Istanbul Medical Journal, 23(2), 119-124., Doi: 10.4274/imj.galenos.2022.40771 Aksoy SH, Yurdaışık I, Timurağaoğlu A.
  • The Efficacy and Safety of Busulfan-Etoposide-Melphalan Regimen in Autologous Stem Cell Transplantation in Relapsed/ Refractory Hodgkin and Non-Hodgkin Lymphoma Patients: ?A Single-Center Experience İstanbul Med J 2021; 22: 133-9. Eser A, Timurağaoğlu A.
  • Yeni Tanı Multiple Myelomalı hastalarda Lenalidomid İdame Tedavisinin Prognostik Değeri; Tek Merkez Deneyimi-Geriye Dönük Çalışma Van Tıp Derg, 28: 221-226, 2021. A. Eser, A. Timurağaoğlu.
  • The Efficacy of Eltrombopag Treatment in Patients who developed Platelet Engraftment Failure after Allogeneic Stem Cell Transplantation: A Single Center Experience. Bezmialem Science, 9: 98-105, 2021. A. Eser, A. Timurağaoğlu.
  • Effect of single agent bortezomib as post-transplant consolidation therapy on multiple myeloma related bone disease: a randomized phase II study Br J of Haematol 2017; 178: 61-71. Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, Meltem Akay O, Gülbas Z, Nahi H, Plesner T, Snowden JA, Timurağaoğlu A, Dechow T, Lang A,
.
.
.

Contact Us

Fill out the form below for your information requests

As Acıbadem Healthcare Group, you can report your requests, suggestions, thanks and complaints by filling out the form below or by contacting us at +90 538 685 39 52 so that we can provide you with a better and higher quality service.

See More
See More
Security Code

INFORMATION NOTICE ON THE PROCESSING OF PERSONAL DATA

Acıbadem Sağlık Hizmetleri ve Ticaret A.Ş. and its controlling and affiliated companies listed in Annex-1 (each referred to individually as the "Company" and collectively as the "Companies") process your general and/or special category personal data (including but not limited to health data) ("Personal Data") in the capacity of Data Controller under the Personal Data Protection Law No. 6698 ("Law") and related legislation. Processing of Personal Data is carried out in accordance with the framework outlined below and in compliance with the Fundamental Law on Health Services No. 3359, the Decree Law No. 663 on the Organization and Duties of the Ministry of Health and its Affiliated Institutions, the Regulation on the Provision of Remote Health Services, the Private Hospitals Regulation, the Ministry of Health regulations, and other relevant legislation.

I. Acquisition, Processing, and Purposes of Processing Personal Data

Your Personal Data is obtained through verbal, written, visual, or electronic channels (such as our website, mobile applications, and call center) for the purposes of protecting public health, preventive medicine, medical diagnosis, treatment and care services, and the planning and management of healthcare services and their financing, in alignment with the Company's fields of activity. The Personal Data processed by the Company, including but not limited to the following, is collected and processed proportionally and in connection with these purposes:

Your Personal Data may be processed under the conditions specified in Articles 5 and 6 of the Law for the following purposes:

II. Transfer of Personal Data

Your Personal Data may be shared with:

III. Method and Legal Basis for Collecting Personal Data

Your Personal Data is collected through verbal, written, visual, or electronic means for the lawful execution of the Company's activities and compliance with contractual and legal obligations. The legal basis for collection includes:

As per Article 6 - (3) of the Law, personal data related to health and sexual life may be processed without explicit consent by persons or institutions subject to confidentiality obligations for public health protection, preventive medicine, medical diagnosis, treatment, and care services, as well as the planning and management of healthcare financing.

IV. Your Rights Regarding the Protection of Personal Data

Under Article 11 of the Law, you have the right to:

V. Data Security

The Companies ensure the security of Personal Data by implementing necessary technical and administrative measures in accordance with information security standards and procedures.

VI. Complaints and Contact Information

To exercise your rights under the Law, you may submit a request through the methods specified in the "Acıbadem Sağlık Hizmetleri ve Ticaret A.Ş. Data Subject Application Form" available at https://www.acibadem.com.tr/acibademonline/images/Ac%C4%B1badem_Veri_Sahibi_Basvuru_Formu.pdf.

Requests can be submitted by mail, notarized document, or secure electronic means to:

ANNEX-1: List of Companies

 

TOP x""